HIV drug combo fails to trim fat in early trial
NCT ID NCT01420523
First seen Apr 18, 2026 · Last updated May 13, 2026 · Updated 5 times
Summary
This study tested whether switching to a two-drug combination (raltegravir plus maraviroc) could reduce belly fat in people with well-controlled HIV. It included 48 adults who had been on stable HIV therapy for years and had excess belly fat. The trial was stopped early, so the results are limited, but the goal was to find a simpler treatment that also improves body shape.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Pitié Salpétrière
Paris, 75013, France
Conditions
Explore the condition pages connected to this study.